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Summary
Urocortin (UCN), a 40 amino acid peptide, is a corticotrophin-releasing
hormone (CRH)-related peptide. The biological actions of CRH family peptides
are mediated via two types of G-protein-coupled receptors, CRH type 1
(CRHR1) and CRH type 2 (CRHR2). The aim of this study was to investigate
the expression of UCN, CRHR1 and CRHR2 by immunoprecipitation, Western
blot, immunohistochemistry and RT-PCR in the bovine thyroid gland. Immuno-
precipitation and Western blot analysis showed that tissue extracts reacted with
the anti-UCN, anti-CRHR1 and anti-CRHR2 antibodies. RT-PCR experiments
demonstrated that mRNAs of UCN, CRHR1 and CRHR2 were expressed. UCN
immunoreactivity (IR) and CRHR2–IR were found in the thyroid follicular and
parafollicular cells and CRHR1-IR in the smooth muscle of the blood vessels.
These results suggest that a regulatory system exists in the bovine thyroid gland
based on UCN, CRHR1 and CRHR2 and that UCN plays a role in the regulation
of thyroid physiological functions through an autocrine/paracrine mechanism.
Introduction
Urocortin (UCN), a 40-amino acid peptide originally
cloned from the Edinger–Westphal nucleus, is a member
of the corticotrophin-releasing hormone (CRH) family of
peptides (Vaughan et al., 1995). In addition to CRH and
UCN, the CRH family includes the more recently identi-
fied peptides, Urocortin 2 (UCN2) and Urocortin 3
(UCN3) (Lewis et al., 2001; Reyes et al., 2001). The effects
of CRH and UCNs are mediated by the distinct G-coupled
receptors, termed CRH receptor type 1 (CRHR1) and 2
(CRHR2) (Perrin et al., 1993, 2006). These receptors are
encoded by two separate genes and significantly differ in
pharmacological profile, tissue distribution and function,
although they display 70% homology in amino acid
sequence. CRH has a very high affinity for CRHR1. UCN
binds with the same affinity to both receptors, and UCN2
and UCN3 have high affinity to CRHR2 (Tu et al., 2007).
In addition to the receptors, there is a CRH-binding pro-
tein (CRH-BP), which has been reported in mammalian
and non-mammalian vertebrates (Behan et al.,1989; Potter
et al., 1992; Cortright et al.,1995; Seasholtz et al., 2002).
UCN and CRHRs gene expression and/or immunoreactivity
have been detected in several peripheral organs belonging
to digestive, cardiovascular, immune and reproductive sys-
tems (Oki and Sasano, 2004; De Luca et al., 2009; Yang
et al., 2010; Lee et al., 2011).
The presence of UCN and its receptors was, moreover,
reported in several mammalian (Tsatsanis et al., 2007;
Huising et al., 2010; Squillacioti et al., 2011, 2012) endo-
crine glands, thus suggesting a role for this peptide in
regulating endocrine functions.
To further highlight the role of urocortin in the control
of thyroid function, we investigate in this study the
expression and distribution of UCN, CRHR1 and CRHR2
in the bovine thyroid gland. For this purpose, we per-
formed immunoprecipitation, Western blot and immuno-
histochemistry and reverse transcription polymerase chain
reaction (RT-PCR).
Materials and Methods
Animals and tissue collection
This study was performed using adult healthy animals
coming from the same farm located in Southern Italy.
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The animals were bred in natural environmental condi-
tions and were fed hay and concentrate. Water was avail-
able continuously. The animals were sacrificed in a public
slaughterhouse according to the current Italian animal
care protocols. Bovine thyroid and adrenal glands from
these animals were collected in the same day. For Wes-
tern blot and RT-PCR analyses, fresh segments of thyroid
gland and adrenal medulla (positive control) were imme-
diately frozen on dry ice and stored at 80°C. For immu-
nohistochemical studies, fresh segments of thyroid gland
were immediately fixed.
Immunoprecipitation and Western blot analysis
Frozen tissues were homogenised in a buffer (50 mM Tris–
HCl pH 7.00; 150 mM NaCl; 2% Triton; 5 mM EDTA;
10 lg/ml leupeptin; 0.1 U/ml aprotinin; 1 mM PMSF)
using an Ultra-Turrax homogeniser and centrifuged at
16 000 g for 20 min at 4°C. The resulting supernatants
were characterised for protein concentration by Bio-Rad
protein assay. Equal amounts of proteins were immuno-
precipitated overnight at 4°C with anti-UCN, anti-CRHR1
and anti-CRHR2 anti-sera (1 lg antibody/200 lg pro-
teins) previously bound to protein A/G agarose. A fraction
of supernatant was used as an immunoprecipitation input
control (as a loading control). Beads were sedimented by
brief centrifugation and washed extensively with ice-cold
homogenisation buffer. Proteins, solubilised in boiling
sodium dodecyl sulphate (SDS) sample buffer (2% SDS;
5% L-mercaptoethanol; 66 mM Tris pH 7.5; 10 mM
EDTA), were separated on 18% and 12% SDS-polyacryl-
amide gels (Bio-Rad, Hercules, CA, western USA). After
electrophoresis, the gel was transferred to nitrocellulose
using a semi-dry apparatus (Bio-Rad, Hercules, CA, USA)
according to the manufacturer’s instructions. The mem-
brane was incubated for 1 h at 42°C in 5% bovine serum
albumin (BSA; Sigma, St. Louis, MO, USA) in TBST
(150 mM NaCl; 20 mM Tris–HCl pH 7.4; 0.3% Tween-20),
washed with TBST and incubated for 2 h at room temper-
ature (RT) in the anti-sera diluted 1:500 in TBST contain-
ing 1% BSA. The following primary anti-sera were used:
polyclonal goat anti-UCN (sc-1825, diluted 1:1000; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), anti-CRHR1
(sc-12383, diluted 1:1000; Santa Cruz Biotechnology) and
anti-CRHR2 (sc-1826, diluted 1:1000; Santa Cruz Biotech-
nology). The membrane was washed three times with
TBST, incubated for 1 h with anti-goat IgG conjugated to
peroxidase (Vector Laboratories, Burlingame, CA, USA)
diluted 1:2000 in 1% BSA containing TBST and washed
three times with TBST. Proteins were visualised by an
enhanced chemiluminescence kit (Amersham, Bucking-
hamshire, UK). Marker proteins (coloured protein
molecular weight markers; Prosieve, Lonza) were used
to estimate the molecular weight of each band. b-Actin
acted as the input loading control of immunoprecipitat-
ed proteins. A fraction of supernatant (50 lg) was
separated on SDS-PAGE and immunoblotted with an
anti-b-actin primary antibody (Mouse mAb JLA20 cp
01, diluted 1:5000; Calbiochem, San Diego, CA, USA)
and, successively, with a peroxidase-conjugated rabbit
anti-mouse IgG secondary antibody (diluted 1: 2000;
Vector Laboratories).
Immunohistochemistry
Fresh fragments of thyroid gland were fixed by immersion
in Bouin’s fixative (6–24 h), processed for paraffin
embedding in a vacuum and cut at a thickness of
3–6 lm. The avidin–biotin–peroxidase complex (ABC)
method was performed using the Vectastain ABC kit
(Vector Laboratories) as described more fully elsewhere
(Squillacioti et al., 2011). Primary anti-sera were the same
described in detail in the precedent section and were
directed against UCN, CRHR1 and CRHR2 (diluted
1:200). The secondary antibodies were as follows: biotiny-
lated anti-goat IgG (diluted 1:200; Vector Laboratories).
The specificity of the primary immunoreactions was
tested by replacing each antibody with a buffer or pre-
absorbing the antibody with an excess (100 lg antigen/ml
anti-serum as the final dilution) of the relative antigen
or, finally, using a dot-blot assay as described more fully
elsewhere (Squillacioti et al., 2011). No immunoreaction
was detected in control tests. The slides were observed
using a Leica DMRA2 microscope (Leica Microsystems,
Wetzlar, Germany).
RNA extraction, cDNA synthesis, RT-PCR and
sequencing
Samples of the frozen thyroid tissue were individually
homogenised in ice-cold TRI-Reagent (Sigma) using an
Ultra-Turrax homogeniser. After chloroform extraction
and isopropyl alcohol precipitation, RNA was dissolved
in RNase-free DEPC water. Total RNA was measured
with an Eppendorf Biophotometer (Eppendorf AG, Basel,
Switzerland). For cDNA synthesis, 1 lg of total RNA was
retrotranscribed with the High Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Foster City, CA,
USA) and random hexamers as primers. For PCRs, spe-
cific primers for bovine UCN, CRH-R1 and CRH-R2
were designed from the published gene sequences using
the Primer ExpressTM software (PE Applied Biosystems) as
described elsewhere (Squillacioti et al., 2011). To verify
the efficiency of the reverse transcription (RT) and to
exclude genomic DNA contamination, a fragment of b-
actin cDNA (GenBank accession number NM_173979)
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was amplified and sequenced with primers designed to
span an intron. The sense and anti-sense beta-actin prim-
ers were 5′-CAG CTC CTC CCT GGA GAA GA-3′ and
5′-CTG CTT GCT GAT CCA CAT CTG-3′, which
amplify a 398-bp fragment. The PCR cycle conditions
were as follows: 94°C (30 s), 60°C (30 s), 72°C (1 min)
for 35 cycles; 72°C (5 min). A sample without cDNA
template was used to verify that the master mix was free
from contaminants. PCR products were electrophoresed
on a 1.5% agarose gel and visualised under UV light. The
PCR products of bovine UCN, CRHR1, CRHR2 were
purified using GFX PCR DNA and Gel Purification Kit
(code 28-9034-70, GE Healthcare) and sequenced.
Results
Immunoprecipitation and Western blot
The results of the immunoprecipitation and Western blot
analysis are shown in Fig. 1. Tissue extracts of the bovine
thyroid gland reacted with the anti-UCN, anti-CRHR1
and anti-CRHR2 antibodies.
Thyroid tissue extracts and the synthetic peptide UCN
reacted with the anti-UCN antibody (Fig. 1). The anti-
body recognised one major protein band of approxi-
mately 16 kDa from homogenates and one protein band
of approximately 6.5 kDa from the synthetic peptide.
The thyroid tissue extracts also reacted with the
anti-CRHR1 and anti-CRHR2 antibodies (Fig. 1). The
antibodies recognised one protein band measuring
approximately 55 kDa.
Immunohistochemistry
In the bovine thyroid gland, UCN immunoreactivity (IR)
was found in follicular (Fig. 2a) and parafollicular cells
(C cells) (Fig. 2b). In the follicular cells, the immunopos-
itive material had a supranuclear distribution. CRHR2-IR
was also found in the follicular and parafollicular cells
(Figs 2c and 3d). Parafollicular cells were larger than fol-
licular and had large rounded nuclei. They usually did
not reach the lumen of the follicles (Fig 2b,d). The distri-
bution of CRHR1-IR was different from UCN and
CRHR2. CRHR1-IR was found only in the smooth mus-
culature of blood vessels (Fig. 2e,f).
RT-PCR
RT-PCR experiments demonstrated that UCN, CRHR1
and CRHR2 mRNAs were expressed in the thyroid gland
(Fig. 3).
Discussion
The results of the present study revealed the presence of
UCN, CRHR1 and CRHR2 mRNAs and proteins in the
bovine thyroid gland.
Up until now, the expression of UCN and CRHRs in
non-pathological thyroid tissue has only been reported in
the horse (Squillacioti et al., 2012). CRH, UCN and
UCN3 have been also reported in the human thyroid
gland in cases of multiple endocrine neoplasia type II
accompanied by thyroid medullary carcinoma and phaeo-
chromocytomas (Kageyama et al., 2008). CRH-IR, more-
over, has been detected in thyroid lesions, predominantly
in those related to autoimmune phenomena (Scopa et al.,
1994).
Immunoprecipitation and Western blot analysis
showed that the anti-mammalian UCN antibody used in
the present study recognised a protein band with a
molecular weight of approximately 16 kDa in the bovine
thyroid gland. This protein is comparable with the mam-
malian UCN precursor, which is a 122-amino acid pro-
tein (Vaughan et al., 1995; Donaldson et al., 1996;
Squillacioti et al., 2011). The antibodies used against
CRHR1 and CRHR2 recognised protein bands with
molecular weights of approximately 55 kDa. These pro-
teins are comparable with the mammalian CRH receptors
(Chen et al., 1993; Perrin et al., 2006).
The results of the present study showed that in the
bovine thyroid gland, UCN- and CRHR2-IRs were found
in the follicular and parafollicular cells. These results dif-
fer from those reported in the horse thyroid gland where
UCN-IR was found in follicular and CRHR2-IR in para-
follicular cells (Squillacioti et al., 2012). UCN may play
Fig. 1. Expression of UCN, CRHR1 and CRHR2 by immunoprecipitation
and Western blot analysis in the bovine thyroid gland. Tissue extracts
were immunoprecipitated and immunoblotted with anti-UCN, anti-
CRHR1 and anti-CRHR2 antibodies; UCN synthetic peptide (100 ng/
lane) and bovine adrenal medulla were used as positive controls.
Beta-actin acted as the input loading control of immunoprecipitated
proteins. Molecular weight markers are in kDa.
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some roles in the regulation of thyroid functions such as
Ca2+ metabolism and hormone secretion. Besides the
extrathyroidal main regulation, thyroid functions and
growth are under the influence of intrathyroidal peptides.
There is evidence of the role played by some local factors
released by nerve endings, such as vasointestinal peptide
(VIP) or neuropeptide Y (Ahren, 1989), by follicular cells
themselves, such as insulin-like growth factors (IGFs)
(review, Eggo et al., 2003) or GHrelin (Morillo-Bernal
et al., 2011), and by parafollicular cells such as serotonin
and calcitonin gene-related peptide (CGRP) (Ahren,
1991; Utrilla et al., 2013). Functional interaction between
follicular and parafollicular cells mediated by the release
of the peptidergic hormones or neuropeptides seems to
exist (Bernal et al., 2009; Morillo-Bernal et al., 2011).
Thyroid follicular cells are responsible for the thyroglobu-
lin synthesis, iodine uptake and thyroid hormone synthe-
sis. The production and secretion of thyroxine and
triiodothyronine by the thyroid gland are stimulated by
the hypothalamic hormone thyrotropin-releasing hor-
mone (TRH) and the anterior pituitary hormone TSH.
Thyroid parafollicular cells are mainly known for produc-
ing calcitonin, a hormone involved in calcium homeosta-
sis with hypocalcaemic and hypophosphataemic effects.
(a) (b)
(c) (d)
(e) (f)
Fig. 2. Distribution of the UCN, CRHR1 and
CRHR2 immunoreactivities in the bovine thy-
roid gland. UCN-IR was distributed in the api-
cal portion of the thyroid follicular cells (a)
(arrows) and in the thyroid parafollicular cells
(b) (arrow head). CRHR2-IR was distributed in
the thyroid follicular (c) and parafollicular cells
(d). CRHR1-IR was found in the vascular
smooth muscle (e, f) (double arrows) of the
thyroid blood vessels. FL Follicular lumen
bar = 25 micron.
Fig. 3. UCN, CRHR1 and CRHR2 expression by RT-PCR in the bovine
thyroid gland. UCN (200-bp fragment), (2) CRH-R2 (200-bp frag-
ment), (3) CRH-R1 (409-bp fragment) were expressed in the bovine
thyroid gland. Molecular weight marker was a 100-bp ladder.
© 2013 Blackwell Verlag GmbH
Anat. Histol. Embryol. 43 (2014) 429–434432
Urocortinergic System in the Bovine Thyroid C. Squillacioti et al.
Our results suggest that UCN could affect thyroid hor-
mones and calcitonin secretion via CRHR2 in an auto-
crine/paracrine manner. In addition, other CRHR2
ligands, such as UCN2 and UCN3, probably interact with
this receptor to regulate follicular and parafollicular cell
activity.
CRHR1-IR was found in the vascular smooth muscula-
ture, thus suggesting a role for UCN in modulating the
thyroid gland blood flow. This hypothesis is corroborated
by the fact that UCN was found to be a dilator of rat
(Lubomirov et al., 2001; Abdelrahman et al., 2005) and
mouse (Lubomirov et al., 2006) arteries.
The thyroid blood flow together with TSH regulates
the uptake of iodide by the thyroid gland (Ingbar et al.,
1986; Arntzenius et al., 1991). Iodide is an essential ele-
ment for the production of thyroid hormones. Alterations
in the thyroidal uptake of iodide can cause changes in the
production of thyroid hormones, and the regulation of
the iodide uptake is very important for the thyroid gland
activity.
In conclusion, these results suggest that UCN, CRHR1
and CRHR2 are expressed in the bovine thyroid gland
and that a local regulatory system of thyroid functions
based on the UCN and CRHRs exists. UCN plays a role
in the regulation of the blood flow of this gland via
CRHR1 and of the thyroid hormones synthesis via
CRHR2 by an autocrine/paracrine mechanism.
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